THE GLOBAL BURDEN OF HEART FAILURE: A SYSTEMATIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2021

Document ID: SC-VN-04086 | Author: 
Boehringer Ingelheim Download
 
 

NHỮNG NỘI DUNG LIÊN QUAN

/vn/resources/metabolic/empagliflozin/2023-focused-update-esc-guidelines-chronic-heart-failure
2023 FOCUSED UPDATE OF THE ESC GUIDELINES FOR CHRONIC HEART FAILURE
/vn/resources/metabolic/empagliflozin/de-novo-heart-failure-when-start-treatment-arni-and-sglt2i
DE NOVO HEART FAILURE: WHEN TO START TREATMENT WITH AN ARNI AND SGLT2I
/vn/resources/metabolic/empagliflozin/global-challenges-heart-failure-what-can-we-learn-each-other
GLOBAL CHALLENGES IN HEART FAILURE: WHAT CAN WE LEARN FROM EACH OTHER?
/vn/resources/metabolic/empagliflozin/practical-guidance-implement-heart-failure-treatment-sglt2i-hospital-setting
PRACTICAL GUIDANCE TO IMPLEMENT HEART FAILURE TREATMENT WITH SGLT2I IN THE HOSPITAL SETTING
/vn/resources/metabolic/empagliflozin/practical-guidance-implement-heart-failure-treatment-sglt2i-outpatient-setting
PRACTICAL GUIDANCE TO IMPLEMENT HEART FAILURE TREATMENT WITH SGLT2I IN THE OUTPATIENT SETTING
/vn/resources/metabolic/empagliflozin/baseline-characteristics-patients-enrolled-empact-mi-trial
BASELINE CHARACTERISTICS OF PATIENTS ENROLLED IN THE EMPACT-MI TRIAL
/vn/resources/metabolic/empagliflozin/record-mi-heart-failure-complicating-acute-myocardial-infarction
RECORD MI: HEART FAILURE COMPLICATING ACUTE MYOCARDIAL INFARCTION